Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

R-oxybutynin · Ditropan, Ditropan Xl

Small molecule · Antagonist of muscarinic acetylcholine receptor · developed by Janssen Pharms

Approved FDA, Jul 1975
1 Registered trials

What is R-oxybutynin?

R-oxybutynin is the R-isomer of oxybutynin, the isomer that carries most of the antimuscarinic activity of the racemic mixture. It acts as a competitive antagonist of acetylcholine at postganglionic muscarinic receptors, relaxing bladder smooth muscle. It is being studied in obstructive sleep apnea, given orally before bed.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Ditropan, Ditropan Xl, Gelnique, Oxytrol
Drug type
Small molecule
Targets
muscarinic acetylcholine receptor
Mechanism
Antagonist of muscarinic acetylcholine receptor
Pathways
acetylcholine signaling at postganglionic muscarinic receptors, detrusor smooth muscle relaxation
Therapy area
Respiratory
Developer
Janssen Pharms
In trials of
APMD
FDA status
Approved as Ditropan, Ditropan Xl, Gelnique (July 16, 1975), NDA017577 · FDA label
UNII
5BRQ29UUB7

✅ FDA-approved uses

From the indications section of the FDA label (version of May 29, 2024). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04580394 Phase 2 Obstructive Sleep Apnea Completed APMD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Obstructive Sleep Apnea

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.